Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.
The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.
A user shared a discount code for RU58841 from Anagen Inc, which some users find effective for hair loss without side effects. Another user expressed skepticism about the safety of RU58841 due to limited research.
User asks about CB-03-01 for hair loss treatment and mentions using topical Dutasteride, TRT, and considering mixing CB-03-01 with Fluridil. CB-03-01 is sold at a high price, and user considers trying a lower concentration.
The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.
Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.
A 22-year-old with 4c hair is considering a hair transplant to address traction alopecia caused by braid extensions. They have tried derma stamping, oils, and minoxidil but stopped due to side effects.
The user is asking for opinions on whether their hair growth is due to Pantostin and hormone treatments. One commenter confirms regrowth and asks about the hormone treatments.
A user suggests that deeper microneedling with Verteporfin injections might help regrow hair in areas with scar tissue, alongside a DHT blocker. Another user explains that hair loss might be due to reduced Wnt/β-Catenin signaling and suggests that treatments like Minoxidil, Finasteride, and microneedling could potentially reverse it.
Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.
The user is unsatisfied with their hair transplant and is considering another transplant, PRP, exosomes, or stem cells. They currently use topical minoxidil, dutasteride, and tretinoin.
The user reduced serum DHT by 60% using Advanced Trichology's natural DHT blocker but saw no improvement in hair loss. They are considering switching to finasteride due to its proven effectiveness in inhibiting scalp DHT.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.
A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.
RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.
Rating treatments for hair loss, with the help of GPT-4, according to efficacy, evidence and tolerability; a combination of chemicals from research papers, custom compounds, and some suggestions from other users were included.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.
A 26-year-old individual treating hair loss since 19, using a regimen of Finasteride, Cyproterone, Oral Minoxidil, Microneedling, Dutasteride, and newly added RU58841. They're seeking advice from other RU58841 users about their experiences.
Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.
The user has been using finasteride and minoxidil with tretinoin for 5 months and is questioning if they see hair regrowth. Others share their experiences and challenges with hair loss treatments, particularly the availability of medications.
The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.
The user shared their hair regrowth journey using treatments like dutasteride, minoxidil, microneedling, tretinoin, Nizoral, silica, biotin, and hormone replacement therapy (HRT) with cyproterone and estradiol. They reported substantial hairline improvement and some crown thinning, with hopes for further progress.
The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.
The conclusion of the conversation is that the user, AlgomasReturns, tried various treatments for hair loss but saw regrowth after starting finasteride. They recommend others to try it as well.
Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.